Menu Search
Equities

Tilray Brands Inc

TLRY:TOR

Tilray Brands Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)2.43
  • Today's Change-0.01 / -0.41%
  • Shares traded816.98k
  • 1 Year change-26.36%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.

  • Revenue in USD (TTM)788.94m
  • Net income in USD-244.98m
  • Incorporated2018
  • Employees2.65k
  • Location
    Tilray Brands Inc655 Madison Avenue, 19Th FloorNEW YORK 10065United StatesUSA
  • Phone+1 (416) 934-2141
  • Fax+1 (416) 934-2141
  • Websitehttps://www.tilray.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.